"It may be possible to use available drugs on the shelf that are effective in melanoma to treat myeloma patients with similar mutations," said Kenneth Anderson, the program director and chief of hematologic neoplasias at the Dana-Farber Cancer Institute, adding that he envisions a "very rapid bench-to-bedside translation."